PAVS
Paranovus Entertainment Technology Ltd.
Packaged Foods
Market Cap$69K
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PAVS vs XTLB
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$279K
5Y Perf.-52.6%
PAVS vs XTLB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PAVS | XTLB |
|---|---|---|
| Industry | Packaged Foods | Biotechnology |
| Market Cap | $69K | $279K |
| Revenue (TTM) | $13M | $451K |
| Net Income (TTM) | $-27M | $-1M |
| Gross Margin | 11.1% | 26.4% |
| Operating Margin | -10.3% | -481.6% |
| Forward P/E | 0.0x | — |
| Total Debt | $2M | $138K |
| Cash & Equiv. | $261K | $371K |
PAVS vs XTLB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PAVS
XTLB
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Paranovus Entertain… (PAVS) | 100 | 0.0 | -100.0% |
| XTL Biopharmaceutic… (XTLB) | 100 | 47.4 | -52.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PAVS vs XTLB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PAVS leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. XTL Biopharmaceuticals Ltd. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
PAVS
Paranovus Entertainment Technology Ltd.
The Income Pick
PAVS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.53
- Rev growth -98.9%, EPS growth 96.4%, 3Y rev CAGR -84.9%
- Lower volatility, beta 1.53, Low D/E 8.1%, current ratio 1.12x
Best for: income & stability and growth exposure
XTLB
XTL Biopharmaceuticals Ltd.
The Long-Run Compounder
XTLB is the clearest fit if your priority is long-term compounding.
- -87.9% 10Y total return vs PAVS's -100.0%
- -52.3% vs PAVS's -99.9%
- -17.7% ROA vs PAVS's -94.4%, ROIC -54.1% vs -27.1%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PAVS | -98.9% revenue growth vs XTLB's -173.2% |
| Quality / Margins | PAVS | -211.2% margin vs XTLB's -227.7% |
| Stability / Safety | PAVS | Beta 1.53 vs XTLB's 1.64 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | XTLB | -52.3% vs PAVS's -99.9% |
| Efficiency (ROA) | XTLB | -17.7% ROA vs PAVS's -94.4%, ROIC -54.1% vs -27.1% |
PAVS vs XTLB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLXTLBLAGGINGPAVS
PAVSParanovus Entertainme…
1leads
XTLBXTL Biopharmaceutical…
3leads
6 Total Categories
CATEGORYLEADERvs PAVSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PAVS4/5
Valuation MetricsMultiples, price ratios, and targets
XTLB2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XTLB5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
XTLB6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PAVS leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
PAVS is the larger business by revenue, generating $13M annually — 28.2x XTLB's $451,000. Profitability is closely matched — net margins range from -2.1% (PAVS) to -2.3% (XTLB).
| Metric | PAVSParanovus Enterta… | XTLBXTL Biopharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $13M | $451,000 |
| EBITDAEarnings before interest/tax | $531,773 | -$1M |
| Net IncomeAfter-tax profit | -$27M | -$1M |
| Free Cash FlowCash after capex | -$3M | $0 |
| Gross MarginGross profit ÷ Revenue | +11.1% | +26.4% |
| Operating MarginEBIT ÷ Revenue | -10.3% | -4.8% |
| Net MarginNet income ÷ Revenue | -2.1% | -2.3% |
| FCF MarginFCF ÷ Revenue | -23.5% | -3.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +180.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +76.9% | +20.0% |
PAVS leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
XTLB leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | PAVSParanovus Enterta… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Market CapShares × price | $68,949 | $279,464 |
| Enterprise ValueMkt cap + debt − cash | $2M | $46,464 |
| Trailing P/EPrice ÷ TTM EPS | -0.01x | -0.26x |
| Forward P/EPrice ÷ next-FY EPS est. | 0.00x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.96x | 0.62x |
| Price / BookPrice ÷ Book value/share | 0.00x | 0.05x |
| Price / FCFMarket cap ÷ FCF | — | — |
XTLB leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
XTLB leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
XTLB delivers a -25.5% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-116 for PAVS. XTLB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to PAVS's 0.08x. On the Piotroski fundamental quality scale (0–9), PAVS scores 5/9 vs XTLB's 3/9, reflecting solid financial health.
| Metric | PAVSParanovus Enterta… | XTLBXTL Biopharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -116.2% | -25.5% |
| ROA (TTM)Return on assets | -94.4% | -17.7% |
| ROICReturn on invested capital | -27.1% | -54.1% |
| ROCEReturn on capital employed | -39.5% | -50.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 |
| Debt / EquityFinancial leverage | 0.08x | 0.03x |
| Net DebtTotal debt minus cash | $2M | -$233,000 |
| Cash & Equiv.Liquid assets | $261,355 | $371,000 |
| Total DebtShort + long-term debt | $2M | $138,000 |
| Interest CoverageEBIT ÷ Interest expense | -11.83x | -13.31x |
XTLB leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
XTLB leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XTLB five years ago would be worth $1,846 today (with dividends reinvested), compared to $0 for PAVS. Over the past 12 months, XTLB leads with a -52.3% total return vs PAVS's -99.9%. The 3-year compound annual growth rate (CAGR) favors XTLB at -19.8% vs PAVS's -93.3% — a key indicator of consistent wealth creation.
| Metric | PAVSParanovus Enterta… | XTLBXTL Biopharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -94.9% | +5.8% |
| 1-Year ReturnPast 12 months | -99.9% | -52.3% |
| 3-Year ReturnCumulative with dividends | -100.0% | -48.4% |
| 5-Year ReturnCumulative with dividends | -100.0% | -81.5% |
| 10-Year ReturnCumulative with dividends | -100.0% | -87.9% |
| CAGR (3Y)Annualised 3-year return | -93.3% | -19.8% |
XTLB leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PAVS and XTLB each lead in 1 of 2 comparable metrics.
Risk & Volatility
PAVS is the less volatile stock with a 1.53 beta — it tends to amplify market swings less than XTLB's 1.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XTLB currently trades 24.7% from its 52-week high vs PAVS's 0.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PAVSParanovus Enterta… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.53x | 1.64x |
| 52-Week HighHighest price in past year | $1488.00 | $10.28 |
| 52-Week LowLowest price in past year | $1.02 | $1.05 |
| % of 52W HighCurrent price vs 52-week peak | +0.1% | +24.7% |
| RSI (14)Momentum oscillator 0–100 | 32.5 | 46.2 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 2.4M |
Evenly matched — PAVS and XTLB each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | PAVSParanovus Enterta… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
XTLB leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). PAVS leads in 1 (Income & Cash Flow). 1 tied.
Best OverallXTL Biopharmaceuticals Ltd. (XTLB)Leads 3 of 6 categories
Loading custom metrics...
PAVS vs XTLB: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — PAVS or XTLB?
Over the past 5 years, XTL Biopharmaceuticals Ltd.
(XTLB) delivered a total return of -81. 5%, compared to -100. 0% for Paranovus Entertainment Technology Ltd. (PAVS). Over 10 years, the gap is even starker: XTLB returned -87. 9% versus PAVS's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — PAVS or XTLB?
By beta (market sensitivity over 5 years), Paranovus Entertainment Technology Ltd.
(PAVS) is the lower-risk stock at 1. 53β versus XTL Biopharmaceuticals Ltd. 's 1. 64β — meaning XTLB is approximately 7% more volatile than PAVS relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 8% for Paranovus Entertainment Technology Ltd. — giving it more financial flexibility in a downturn.
03Which has better profit margins — PAVS or XTLB?
XTL Biopharmaceuticals Ltd.
(XTLB) is the more profitable company, earning -227. 7% net margin versus -110. 3% for Paranovus Entertainment Technology Ltd. — meaning it keeps -227. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XTLB leads at -481. 6% versus -94. 8% for PAVS. At the gross margin level — before operating expenses — PAVS leads at 12. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — PAVS or XTLB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is PAVS or XTLB better for a retirement portfolio?
For long-horizon retirement investors, Paranovus Entertainment Technology Ltd.
(PAVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. XTL Biopharmaceuticals Ltd. (XTLB) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PAVS: -100. 0%, XTLB: -87. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between PAVS and XTLB?
These companies operate in different sectors (PAVS (Consumer Defensive) and XTLB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.